Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
News May 14, 2015
Horizon Discovery Group plc has appointed Mr Grahame Cook as a Non-Executive Director of the Board with immediate effect. Grahame has also been appointed to the Audit Committee, within which he will assume the role of Chairman.
Grahame Cook is an experienced FTSE and AIM non-executive, with extensive experience as an audit committee chairman. With a background in banking, where he has specialised in the life sciences, pharma and biotech sectors, Grahame has over 20 years’ experience of M&A, equity capital markets and investor relations.
Grahame started his career at Arthur Andersen, where he qualified as a chartered accountant and worked within audit and corporate investigations. Subsequent positions include UBS, where he was a member of the global investment banking management committee and global head of equity advisory, and WestLB Panmure, where he was joint Chief Executive Officer. Grahame currently sits on a number of boards, chairing four, including Sinclair Pharma plc and Morphogenesis Inc.
Grahame is a graduate of the University of Oxford and remains a member of the ICAEW.
Dr. Ian Gilham, Chairman of Horizon’s Board of Directors, commented: “I would like to welcome Grahame to Horizon’s Board and I am confident that Grahame’s significant financial and audit experience in growth-oriented life sciences companies and track record in international capital markets, corporate transactions and strategy-setting will prove to be highly valuable as Horizon continues to grow internationally in fast growing markets.
Mr. Grahame Cook said: “Horizon is an outstanding, innovative company which is becoming a global leader in translational and personalised medicine. I am pleased to join an exceptional board of directors guiding the Company during this important time in its evolution.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE